35868-16-7

Upstream product

• 19234-66-3 2',3'-isopropylideneadenosine-5'-carboxylic acid 
• 847659-02-3 (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(1-hydroxyethyl)tetrahydrofuran-3,4-diol 
• 444809-58-9 (S)-1-((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)ethan-1-ol 
• 68224-54-4 N-(9-((3aR,4R,6R,6aR)-6-((S)-1-hydroxyethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide 
• 43077-09-4 N-(9-((3aR,4R,6S,6aS)-6-acetyl-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide 
• 83376-99-2 1-O-acetyl-2,3,5-tri-O-benzoyl-6-deoxy-α-L-talofuranose 
• 75-36-5 acetyl chloride 

Downstream Products

• 1382467-79-9 {9-[7-(tert-butyl-dimethyl-silanyloxy)-2-methoxy-4-methyl-2-thioxo-tetrahydro-2l5-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-9H-purin-6-yl}-[(4-methoxy-phenyl)-diphenyl-methyl]-amine 
• 1382467-77-7 {9-[7-(tert-butyl-dimethyl-silanyloxy)-2-methoxy-4-methyl-2-oxo-tetrahydro-2l5-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-9H-purin-6-yl}-[(4-methoxy-phenyl)-diphenyl-methyl]-amine 
• 1382467-72-2 4-(tert-butyl-dimethyl-silanyloxy)-2-(1-hydroxy-ethyl)-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 1382467-71-1 2-(1-hydroxy-ethyl)-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3,4-diol 

Relevant academic research and scientific papers

SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

SUBSTITUTED NUCLEOTIDE ANALOGS

Disclosed herein are phosphoroamidate nucleotide analogs, methods of synthesizing phosphoroamidate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the phosphoroamidate

SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS

Disclosed herein are nucleotide analogs with protected phosphates, methods of synthesizing nucleotide analogs with protected phosphates and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with protected phosphates.